Hepatitis D cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Considering that patients who develop [[symptomatic]] [[hepatitis D]] may progress into [[cirrhosis]], [[liver failure]] and [[hepatocellular carcinoma]], adequate therapeutic regimen and | Considering that patients who develop [[symptomatic]] [[hepatitis D]] may progress into [[cirrhosis]], [[liver failure]] and [[hepatocellular carcinoma]], research for an adequate therapeutic regimen and for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective. | ||
==References== | ==References== | ||
Revision as of 00:30, 19 August 2014
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis D cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hepatitis D cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Considering that patients who develop symptomatic hepatitis D may progress into cirrhosis, liver failure and hepatocellular carcinoma, research for an adequate therapeutic regimen and for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective.